{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:54:56Z","timestamp":1790999696609,"version":"4.1.0"},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,10,1]]},"DOI":"10.2169\/internalmedicine.6647-25","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:09:33Z","timestamp":1771884573000},"page":"2573-2579","source":"Crossref","is-referenced-by-count":1,"title":["Immune-mediated Myocarditis after Durvalumab\/tremelimumab Treatment for Unresectable Hepatocellular Carcinoma"],"prefix":"10.2169","volume":"65","author":[{"given":"Shogo","family":"Mawatari","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Miuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisamitsu","family":"Miyaaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1: EVIDoa2100070, 2022.","DOI":"10.1056\/EVIDoa2100070"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 33: 1974-1982, 2015.","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"3","unstructured":"3. Kudo M, Finn RS, Qin S, et al. Himalaya trial: durvalumab and tremelimumab for unresectable hepatocellular carcinoma. Hepatol Int 16: 1005-1017, 2022."},{"key":"4","unstructured":"4. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4: 1721-1728, 2018."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71: 1755-1764, 2018.","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158-168, 2018.","DOI":"10.1056\/NEJMra1703481"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist 23: 879-886, 2018.","DOI":"10.1634\/theoncologist.2018-0130"},{"key":"8","unstructured":"8. Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41: 1733-1743, 2020."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 9: e013757, 2020.","DOI":"10.1161\/JAHA.119.013757"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yamaguchi S, Morimoto R, Okumura T, et al. Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol 34: 812.e1-812.e3, 2018.","DOI":"10.1016\/j.cjca.2018.03.007"},{"key":"11","unstructured":"11. Tocchetti CG, Farmakis D, Ameri P, et al. Cardiac toxicity from immune checkpoint inhibitors: mechanisms, risk factors, and management. Eur Heart J 45: 35-45, 2024."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lipe DN, Qdaisat A, Krishnamani PP, et al. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel) 14: 1794, 2024.","DOI":"10.3390\/diagnostics14161794"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Mark JD, Tapia-Orihuela RKA, Llanos A, et al. Smoldering myocarditis unmasked by pembrolizumab-induced myositis: delayed-onset double M syndrome. JACC Case Rep 30: 105069, 2025.","DOI":"10.1016\/j.jaccas.2025.105069"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/19\/65_6647-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:30:26Z","timestamp":1790998226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/19\/65_6647-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":13,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6647-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"6647-25"}}